text
"['\n3. 타법인출자 현황(상세)\n☞ 본문 위치로 이동\n(기준일 :\xa0\n2023년 06월 30일\n)\n(단위 : 천원, 주, %)\n법인명\n상장여부\n최초취득일자\n출자목적\n최초취득금액\n기초잔액\n증가(감소)\n기말잔액\n최근사업연도재무현황\n수량\n지분율\n장부가액\n취득(처분)\n평가손익\n수량\n지분율\n장부가액\n총자산\n당기순손익\n수량\n금액\n바이오톡스텍\n상장\n2009.07.28\n단순투자\n2,025,000\n1,631,134\n11.12\n13,277,431\n-\n-\n-1,794,248\n1,631,134\n10.22\n11,483,183\n94,314,437\n3,939,312\nA&G Pharmaceutical, Inc\n비상장\n2006.07.14\n단순투자\n2,676,548\n987,889\n16.51\n116,349\n-\n-\n-\n987,889\n16.51\n116,349\n6,070,207\n1,414,454\n매일방송\n비상장\n2011.03.17\n단순투자\n1,000,000\n250,981\n0.48\n1,475,167\n-\n-\n-\n250,981\n0.48\n1,475,167\n429,364,558\n19,159,912\n제이티비씨\n비상장\n2017.09.20\n단순투자\n500,000\n100,000\n0.09\n43,725\n-\n-\n-\n100,000\n0.09\n43,725\n382,224,026\n14,501,439\nAbpro Corporation\n비상장\n2022.09.26\n단순투자\n2,816,797\n111,111\n0.67\n2,816,797\n-\n-\n-\n111,111\n0.65\n2,816,797\n15,003,881\n-14,079,253\nDantari\n비상장\n2022.07.01\n단순투자\n491,016\n910,615\n1.62\n491,016\n-\n-\n-\n910,615\n1.62\n491,016\n16,399,700\n-17,967,270\n피노바이오\n비상장\n2022.10.31\n단순투자\n2,000,310\n66,900\n1.70\n2,000,310\n-\n-\n-\n66,900\n1.28\n2,000,310\n5,900,354\n-15,362,684\n바스젠바이오\n비상장\n2023.04.24\n단순투자\n1,050,000\n-\n-\n-\n7,000\n1,050,000\n-\n7,000\n1.55\n1,050,000\n6,330,623\n-10,955,693\n프리미어 글로벌 이노베이션 1호\n비상장\n2017.06.15\n단순투자\n250,000\n2,590\n6.67\n2,898,171\n-263\n-263,247\n-\n2,327\n6.67\n2,634,924\n37,038,755\n2,923,734\n프리미어 글로벌 이노베이션 2호\n비상장\n2020.11.05\n단순투자\n250,000\n3,700\n5.56\n3,555,844\n250\n250,000\n-\n3,950\n5.56\n3,805,844\n66,666,928\n-846,842\n셀트리온 유럽\n비상장\n2009.07.21\n경영참여\n2\n1\n100.00\n2\n-\n-\n-\n1\n100.00\n2\n2\n-\n셀트리온제약\n상장\n2013.04.23\n경영참여\n50,057,259\n20,678,107\n54.85\n255,342,176\n1,033,905\n-\n-\n21,712,012\n54.82\n255,342,176\n621,743,586\n17,253,152\nCelltrion Global Safety Data Center\n비상장\n2018.05.23\n경영참여\n1,106,930\n580,563\n99.99\n1,204,581\n-\n-\n-\n580,563\n99.99\n1,204,581\n3,020,943\n750,738\nCelltrion Asia Pacific PTE\n비상장\n2020.11.23\n경영참여\n315,987,120\n283,600,000\n100.00\n315,987,120\n-\n-\n-\n283,600,000\n100.00\n315,987,120\n394,396,868\n-1,114,506\nCelltrion Group Hongkong ltd\n비상장\n2019.04.01\n경영참여\n5,680,500\n7,023,270\n70.00\n2,340,622\n-\n-\n-\n7,023,270\n70.00\n2,340,622\n4,696,706\n-666,098\nVcell Shanghai Biotech\n비상장\n2023.01.19\n경영참여\n1,425,590\n-\n-\n-\n-\n1,425,590\n-\n-\n100.00\n1,425,590\n1,492,980\n40,408\n2014 성장사다리-IMM벤처펀드\n비상장\n2014.08.11\n일반투자\n2,000,000\n1,617\n20.00\n800,644\n-1,617\n-800,644\n-\n-\n-\n-\n-\n-2,796,786\n미래에셋 셀트리온신성장 투자조합 1호\n비상장\n2017.03.31\n일반투자\n6,250,000\n458\n50.00\n45,750,000\n-\n-\n-\n458\n50.00\n45,750,000\n115,045,312\n-3,916,459\n미래에셋 셀트리온바이오생태계육성펀드\n비상장\n2021.12.30\n일반투자\n5,000,000\n12,500\n38.46\n12,500,000\n-\n-\n-\n12,500\n38.46\n12,500,000\n30,577,893\n-630,009\n아주-Solasta Life Science 4.0펀드\n비상장\n2022.05.16\n일반투자\n5,000,000\n12,500,000,000\n44.25\n12,500,000\n-\n-\n-\n12,500,000,000\n44.25\n12,500,000\n26,625,149\n-1,049,261\nIksuda Therapeutics Limited\n비상장\n2021.06.01\n경영참여\n9,031,863\n717,112\n16.33\n9,031,863\n594,106\n8,879,530\n-\n1,311,218\n22.38\n17,911,393\n40,343,863\n-10,992,143\n싸이런 테라퓨틱스\n비상장\n2023.05.01\n일반투자\n2,264,621\n-\n-\n-\n80,209\n2,264,621\n-\n80,209\n20.10\n2,264,621\n26,625,149\n-1,049,261\n셀트리온충북대바이오메딕스\n비상장\n2018.07.18\n경영참여\n100,000\n20,000\n50.00\n100,000\n-\n-\n-\n20,000\n50.00\n100,000\n121,864\n-6,160\n합 계\n12,816,698,548\n-\n682,231,818\n1,713,590\n12,805,850\n-1,794,248\n12,818,412,138\n-\n693,243,420\n2,324,003,784\n-21,449,276\n']"
